Study summary

Capivasertib added 7.5 months before progression in PTEN-deficient disease

CAPItello-281 trial (capivasertib) · 1,012 men, phase 3 · Published October 2025, Annals of Oncology

33.2months without progression, vs 25.7 with placebo

What was tested

Capivasertib, an AKT-blocking pill, or placebo added to abiraterone and ADT for metastatic hormone-sensitive prostate cancer that has lost the PTEN protein (about 1 in 4 tumors).

What they found

What it means

First evidence that a PTEN tumor test could guide treatment.

Ann Oncol, via PubMed ↗ Trial record NCT04493853 ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.